多発性骨髄腫の世界市場レポート 2025年

多発性骨髄腫市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR8.1％で383億9,000万米ドルに成長します。予測期間の成長は、医療技術の統合、遠隔医療サービスの採用、個別化ワクチン療法、患者教育のためのデジタルヘルスプラットフォームなどに起因すると考えられます。予測期間の主な動向には、標的療法の進歩、新薬開発、免疫療法の進歩、新規バイオマーカー開発、人工知能の統合などがあります。

多発性骨髄腫市場の予測成長は、この種のがんの有病率の増加によって牽引されると予測されます。形質細胞から発生する多発性骨髄腫は、年齢、遺伝、肥満、放射線被曝などの要因に影響されます。米国がん学会が報告しているように、症例数の増加は明らかであり、新規症例数は2022年の34,470例から2023年には35,730例に増加します。このような有病率の上昇は、多発性骨髄腫治療における進歩の必要性を強調し、市場の成長に寄与しています。

ヘルスケア支出の増加は多発性骨髄腫市場を前進させる。ヘルスケア支出は、定義された期間内のヘルスケア商品およびサービスに対する総支出額を表し、多発性骨髄腫の治療および管理において重要な役割を果たします。これらの支出は、治療、投薬、入院、支持療法など様々な側面をカバーしています。カナダ保健情報研究所（CIHI）が2022年11月に示したように、カナダにおける総医療支出の2021年の3,280億米ドルから2022年の3,310億米ドルへの増加予測は、ヘルスケアへの財政支出の増加を反映しています。このような医療費の増加動向は、多発性骨髄腫治療オプションの進歩を促進し、市場全体の成長に貢献すると予想されます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界多発性骨髄腫PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の多発性骨髄腫市場：成長率分析
• 世界の多発性骨髄腫市場の実績：規模と成長, 2019-2024
• 世界の多発性骨髄腫市場の予測：規模と成長, 2024-2029, 2034F
• 世界多発性骨髄腫総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の多発性骨髄腫市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 医薬品
• 放射線治療
• 幹細胞移植
• その他の治療法
• 世界の多発性骨髄腫市場診断による、実績と予測, 2019-2024, 2024-2029F, 2034F
• 血液検査
• 骨髄生検
• 尿検査
• 画像検査
• 世界の多発性骨髄腫市場：疾患タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• アクティブ多発性骨髄腫
• くすぶる多発性骨髄腫
• 世界の多発性骨髄腫市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• その他のチャンネル
• 世界の多発性骨髄腫市場、医薬品の種類別の細分化、実績と予測, 2019-2024, 2024-2029F, 2034F
• 免疫調節薬（IMiD）
• プロテアソーム阻害剤
• モノクローナル抗体
• コルチコステロイド
• 化学療法剤
• 世界の多発性骨髄腫市場、放射線治療の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 外部放射線治療（EBRT）
• 放射性同位元素療法
• 世界の多発性骨髄腫市場幹細胞移植の種類別の細分化、実績と予測, 2019-2024, 2024-2029F, 2034F
• 自家幹細胞移植（ASCT）
• 同種幹細胞移植
• 世界の多発性骨髄腫市場、その他の治療法のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 支持療法
• 臨床試験と実験的治療

第7章 地域別・国別分析

• 世界の多発性骨髄腫市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の多発性骨髄腫市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 多発性骨髄腫市場：競合情勢
• 多発性骨髄腫市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Private Limited Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bayer AG
• Novartis AG
• Sanofi S.A.
• Bristol-Myers Squibb Company
• AstraZeneca plc
• Abbott Laboratories
• GlaxoSmithKline PLC
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Boehringer Ingelheim International GmbH
• Amgen Inc.
• Janssen Global Services LLC
• Celgene Corporation
• Mylan N.V.
• Biogen Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 多発性骨髄腫市場2029：新たな機会を提供する国
• 多発性骨髄腫市場2029：新たな機会を提供するセグメント
• 多発性骨髄腫市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Multiple myeloma is a form of cancer originating in a type of white blood cell known as a plasma cell. In this condition, cancerous plasma cells accumulate in the bone marrow, displacing healthy blood cells. The cancer cells produce abnormal proteins that can lead to complications rather than contributing to the production of beneficial antibodies.

The primary treatments for multiple myeloma encompass various approaches such as medications, radiation therapy, stem cell transplant, and others. Medications, in this context, refer to dosage forms containing both potentially inert substances and one or more active chemicals aimed at managing the disease. To diagnose active multiple myeloma and smoldering multiple myeloma, healthcare professionals employ blood tests, bone marrow biopsy, urine tests, and imaging tests. Treatment modalities can be administered through different channels, including hospital pharmacies, retail pharmacies, online pharmacies, and other distribution channels.

The multiple myeloma research report is one of a series of new reports from The Business Research Company that provides multiple myeloma market statistics, including the multiple myeloma industry's global market size, regional shares, competitors with multiple myeloma market share, detailed multiple myeloma market segments, market trends and opportunities, and any further data you may need to thrive in the multiple myeloma industry. This multiple myeloma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The multiple myeloma market size has grown strongly in recent years. It will grow from $26.07 billion in 2024 to $28.15 billion in 2025 at a compound annual growth rate (CAGR) of 8.0%. The growth in the historic period can be attributed to diagnostic improvements, the introduction of stem cell transplantation, access to high-quality medical care, precision medicine approaches, and patient-centric care models

The multiple myeloma market size is expected to see strong growth in the next few years. It will grow to $38.39 billion in 2029 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to health technology integration, adoption of telemedicine services, personalized vaccine therapies, and digital health platforms for patient education. Major trends in the forecast period include advancements in targeted therapies, novel drug development, immunotherapy advancements, novel biomarker development, and integration of artificial intelligence.

The anticipated growth in the multiple myeloma market is expected to be driven by the increasing prevalence of this form of cancer. Multiple myeloma, which originates in plasma cells, is influenced by factors such as age, genetics, obesity, and radiation exposure. The rise in the number of cases is evident, as reported by the American Cancer Society, with new cases increasing from 34,470 in 2022 to 35,730 in 2023. This escalation in prevalence underscores the imperative for advancements in multiple myeloma treatments, thereby contributing to the growth of the market.

The growth in healthcare expenditures is poised to propel the multiple myeloma market forward. Healthcare expenditures, representing the total monetary outlay on healthcare goods and services within a defined period, play a significant role in the treatment and management of multiple myeloma. These expenditures cover various aspects, including therapies, medications, hospitalization, and supportive care. As indicated by the Canadian Institute for Health Information (CIHI) in November 2022, the forecasted rise in total health spending in Canada from $328 billion in 2021 to $331 billion in 2022 reflects the increasing financial commitment to healthcare. This upward trend in healthcare expenditures is expected to drive advancements in multiple myeloma treatment options and contribute to the overall growth of the market.

Product innovation stands out as a prominent trend in the multiple myeloma market, with major companies actively engaged in developing innovative therapies to maintain their competitive positions. In October 2022, Janssen Pharmaceutical Companies of Johnson & Johnson achieved FDA approval for TECVAYLI (teclistamab-cqyv), the first bispecific T-cell engager antibody. This drug is intended for the treatment of adult patients with multiple myeloma who have undergone at least four prior lines of therapy, including various drugs. TECVAYLI targets the B-cell maturation antigen (BCMA) expressed on certain B-lineage cells, as well as the CD3 receptor found on T-cells and multiple myeloma cells.

Major players in the multiple myeloma market are also focusing on the development of novel therapies such as CAR T-cell therapy (Chimeric Antigen Receptor T-cell therapy) to gain a competitive advantage. In December 2023, Bristol Myers Squibb received approval for Abecma, the first CAR T-cell therapy for earlier use in patients with relapsed or refractory multiple myeloma who have undergone at least two prior therapies. Abecma, a B-cell maturation antigen (BCMA)-directed CAR T-cell immunotherapy, demonstrated significant improvements in median progression-free survival (mPFS) and overall response rate (ORR) based on the interim analysis of the KarMMa-3 Phase 3 study.

In February 2024, AstraZeneca Plc, a UK-based pharmaceutical company, acquired Gracell Biotechnologies Inc. for an undisclosed amount. This acquisition highlights AstraZeneca's strategic effort to bolster its presence in immuno-oncology and cellular therapies by leveraging Gracell's cutting-edge platform and expertise. Gracell Biotechnologies Inc., a China-based company, specializes in the clinical development of FasTCAR-T GC012F for the treatment of multiple myeloma.

Major companies operating in the multiple myeloma market include Pfizer Inc., Johnson & Johnson Private Limited, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Amgen Inc., Janssen Global Services LLC, Celgene Corporation, Mylan N.V., Biogen Inc., Cipla Inc., Sun Pharmaceutical Industries Ltd., CRISPR Therapeutics AG, Karyopharm Therapeutics Inc., Fate Therapeutics Inc., Atara Biotherapeutics Inc., Allogene Therapeutics Inc., C4 Therapeutics Inc., Adaptimmune Therapeutics plc, Precision Biosciences Inc.

North America was the largest region in the multiple myeloma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the multiple myeloma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the multiple myeloma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The multiple myeloma market consists of revenues earned by entities by providing services such as treatment planning, supportive care, and diagnostic testing such as computerized tomography (CT scans), magnetic resonance imaging (MRI), and positron emission tomography (PET) scans. The market value includes the value of related goods sold by the service provider or included within the service offering. The multiple myeloma market also includes sales of thalidomide, bortezomib, and daratumumab which are used in providing multiple myeloma services. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Multiple Myeloma Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on multiple myeloma market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for multiple myeloma ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The multiple myeloma market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment: Medications; Radiation Therapy; Stem Cell Transplant; Other Treatments
• 2) By Diagnosis: Blood Tests; Bone Marrow Biopsy; Urine Tests; Imaging Tests
• 3) By Disease Type: Active Multiple Myeloma; Smoldering Multiple Myeloma
• 4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Channels
• Subsegments:
• 1) By Medications: Immunomodulatory Drugs (IMiDs); Proteasome Inhibitors; Monoclonal Antibodies; Corticosteroids; Chemotherapy Agents
• 2) By Radiation Therapy: External Beam Radiation Therapy (EBRT); Radioisotope Therapy
• 3) By Stem Cell Transplant: Autologous Stem Cell Transplant (ASCT); Allogeneic Stem Cell Transplant
• 4) By Other Treatments: Supportive Care; Clinical Trials And Experimental Therapies
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson Private Limited; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Multiple Myeloma Market Characteristics

3. Multiple Myeloma Market Trends And Strategies

4. Multiple Myeloma Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Multiple Myeloma Growth Analysis And Strategic Analysis Framework

• 5.1. Global Multiple Myeloma PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Multiple Myeloma Market Growth Rate Analysis
• 5.4. Global Multiple Myeloma Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Multiple Myeloma Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Multiple Myeloma Total Addressable Market (TAM)

6. Multiple Myeloma Market Segmentation

• 6.1. Global Multiple Myeloma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Medications
• Radiation Therapy
• Stem Cell Transplant
• Other Treatments
• 6.2. Global Multiple Myeloma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Blood Tests
• Bone Marrow Biopsy
• Urine Tests
• Imaging Tests
• 6.3. Global Multiple Myeloma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Active Multiple Myeloma
• Smoldering Multiple Myeloma
• 6.4. Global Multiple Myeloma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Other Channels
• 6.5. Global Multiple Myeloma Market, Sub-Segmentation Of Medications, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immunomodulatory Drugs (IMiDs)
• Proteasome Inhibitors
• Monoclonal Antibodies
• Corticosteroids
• Chemotherapy Agents
• 6.6. Global Multiple Myeloma Market, Sub-Segmentation Of Radiation Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• External Beam Radiation Therapy (EBRT)
• Radioisotope Therapy
• 6.7. Global Multiple Myeloma Market, Sub-Segmentation Of Stem Cell Transplant, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Autologous Stem Cell Transplant (ASCT)
• Allogeneic Stem Cell Transplant
• 6.8. Global Multiple Myeloma Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Supportive Care
• Clinical Trials And Experimental Therapies

7. Multiple Myeloma Market Regional And Country Analysis

• 7.1. Global Multiple Myeloma Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Multiple Myeloma Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Multiple Myeloma Market

• 8.1. Asia-Pacific Multiple Myeloma Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Multiple Myeloma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Multiple Myeloma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Multiple Myeloma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Multiple Myeloma Market

• 9.1. China Multiple Myeloma Market Overview
• 9.2. China Multiple Myeloma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Multiple Myeloma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Multiple Myeloma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Multiple Myeloma Market

• 10.1. India Multiple Myeloma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Multiple Myeloma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Multiple Myeloma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Multiple Myeloma Market

• 11.1. Japan Multiple Myeloma Market Overview
• 11.2. Japan Multiple Myeloma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Multiple Myeloma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Multiple Myeloma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Multiple Myeloma Market

• 12.1. Australia Multiple Myeloma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Multiple Myeloma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Multiple Myeloma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Multiple Myeloma Market

• 13.1. Indonesia Multiple Myeloma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Multiple Myeloma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Multiple Myeloma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Multiple Myeloma Market

• 14.1. South Korea Multiple Myeloma Market Overview
• 14.2. South Korea Multiple Myeloma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Multiple Myeloma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Multiple Myeloma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Multiple Myeloma Market

• 15.1. Western Europe Multiple Myeloma Market Overview
• 15.2. Western Europe Multiple Myeloma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Multiple Myeloma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Multiple Myeloma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Multiple Myeloma Market

• 16.1. UK Multiple Myeloma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Multiple Myeloma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Multiple Myeloma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Multiple Myeloma Market

• 17.1. Germany Multiple Myeloma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Multiple Myeloma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Multiple Myeloma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Multiple Myeloma Market

• 18.1. France Multiple Myeloma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Multiple Myeloma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Multiple Myeloma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Multiple Myeloma Market

• 19.1. Italy Multiple Myeloma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Multiple Myeloma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Multiple Myeloma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Multiple Myeloma Market

• 20.1. Spain Multiple Myeloma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Multiple Myeloma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Multiple Myeloma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Multiple Myeloma Market

• 21.1. Eastern Europe Multiple Myeloma Market Overview
• 21.2. Eastern Europe Multiple Myeloma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Multiple Myeloma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Multiple Myeloma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Multiple Myeloma Market

• 22.1. Russia Multiple Myeloma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Multiple Myeloma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Multiple Myeloma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Multiple Myeloma Market

• 23.1. North America Multiple Myeloma Market Overview
• 23.2. North America Multiple Myeloma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Multiple Myeloma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Multiple Myeloma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Multiple Myeloma Market

• 24.1. USA Multiple Myeloma Market Overview
• 24.2. USA Multiple Myeloma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Multiple Myeloma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Multiple Myeloma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Multiple Myeloma Market

• 25.1. Canada Multiple Myeloma Market Overview
• 25.2. Canada Multiple Myeloma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Multiple Myeloma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Multiple Myeloma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Multiple Myeloma Market

• 26.1. South America Multiple Myeloma Market Overview
• 26.2. South America Multiple Myeloma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Multiple Myeloma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Multiple Myeloma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Multiple Myeloma Market

• 27.1. Brazil Multiple Myeloma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Multiple Myeloma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Multiple Myeloma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Multiple Myeloma Market

• 28.1. Middle East Multiple Myeloma Market Overview
• 28.2. Middle East Multiple Myeloma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Multiple Myeloma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Multiple Myeloma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Multiple Myeloma Market

• 29.1. Africa Multiple Myeloma Market Overview
• 29.2. Africa Multiple Myeloma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Multiple Myeloma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Multiple Myeloma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Multiple Myeloma Market Competitive Landscape And Company Profiles

• 30.1. Multiple Myeloma Market Competitive Landscape
• 30.2. Multiple Myeloma Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Private Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Multiple Myeloma Market Other Major And Innovative Companies

• 31.1. Bayer AG
• 31.2. Novartis AG
• 31.3. Sanofi S.A.
• 31.4. Bristol-Myers Squibb Company
• 31.5. AstraZeneca plc
• 31.6. Abbott Laboratories
• 31.7. GlaxoSmithKline PLC
• 31.8. Takeda Pharmaceutical Company Limited
• 31.9. Eli Lilly and Company
• 31.10. Boehringer Ingelheim International GmbH
• 31.11. Amgen Inc.
• 31.12. Janssen Global Services LLC
• 31.13. Celgene Corporation
• 31.14. Mylan N.V.
• 31.15. Biogen Inc.

32. Global Multiple Myeloma Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Multiple Myeloma Market

34. Recent Developments In The Multiple Myeloma Market

35. Multiple Myeloma Market High Potential Countries, Segments and Strategies

• 35.1 Multiple Myeloma Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Multiple Myeloma Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Multiple Myeloma Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer